Valneva (NASDAQ:VALN) Stock Rating Upgraded by Wall Street Zen

Key Points

• Valneva has been upgraded to a "hold" rating by Wall Street Zen, reflecting a positive shift in the company's stock outlook.
• Hedge funds and institutional investors have been active in Valneva, with several new positions taken, bringing their ownership to 11.39%.
• For the last quarter, Valneva reported a revenue of $54.84 million, exceeding analysts' expectations of $46.28 million, with an earnings per share of ($0.16).

Wall Street Zen upgraded shares of Valneva (NASDAQ:VALN - Free Report) to a hold rating in a research note published on Saturday.

A number of other equities research analysts have also issued reports on VALN. Jefferies Financial Group set a $14.00 target price on shares of Valneva and gave the stock a "buy" rating in a report on Monday, August 25th. HC Wainwright reaffirmed a "buy" rating and set a $18.00 target price on shares of Valneva in a report on Monday, August 25th. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $15.00.

Valneva Price Performance

NASDAQ:VALN traded up $0.12 during trading hours on Friday, reaching $9.18. 75,895 shares of the company were exchanged, compared to its average volume of 129,271. The company has a current ratio of 2.27, a quick ratio of 1.77 and a debt-to-equity ratio of 0.66. The stock's 50-day moving average is $8.29 and its 200-day moving average is $7.12. The firm has a market cap of $788.84 million, a PE ratio of -9.37 and a beta of 1.79. Valneva has a twelve month low of $3.62 and a twelve month high of $12.25.

Valneva (NASDAQ:VALN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.16) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.11. Valneva had a negative net margin of 33.87% and a negative return on equity of 34.78%. The company had revenue of $54.84 million during the quarter, compared to analysts' expectations of $46.28 million. On average, sell-side analysts anticipate that Valneva will post 0.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Valneva

Hedge funds have recently modified their holdings of the company. GAMMA Investing LLC purchased a new stake in shares of Valneva in the first quarter valued at about $94,000. Marex Group plc purchased a new stake in shares of Valneva in the second quarter valued at about $64,000. Finally, Frazier Life Sciences Management L.P. purchased a new stake in shares of Valneva in the second quarter valued at about $8,240,000. Hedge funds and other institutional investors own 11.39% of the company's stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.